Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES
Executive Summary
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
You may also be interested in...
FDA Approves Abbott Xience DES For Short Dual-Antiplatelet Course
The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.
Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication
The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.
FDA Approves Medtronic’s Resolute Onyx DES With Short-Term Dual-Antiplatelet Therapy
The agency approved Medtronic's zotarolimus-eluting coronary stent for patients with a high bleeding risk who are treated with one month of dual-antiplatelet therapy.